ARE · Q1 2026 Earnings

The framing of public biotech demand collapsed to "unprecedented absence." This quarter Joel said "This is maybe the first quarter in the history of the company that I can remember where we didn't sign a single public biotech lease." The escalation to "zero, first time ever" is the cleanest evidence yet that public biotech leasing is not cyclically depressed but structurally absent. This is no longer a wait-for-the-IPO-window story.

The disposition strategy pivoted from "sell the vacant boxes" to "hold and lease them." For three quarters management framed dispositions as the primary mechanism to recover headline occupancy by removing high-vacancy assets from the denominator. This quarter Marc Binda reversed: "Our initial guidance assumed a 2% benefit, and we now assume around a 1% benefit, as we no longer expect to sell as many assets with significant vacant space." The reason given is positive — emerging leasing interest on assets they'd planned to sell — but the consequence is that the headline occupancy guide drops 150bps because the cleansing mechanism has been narrowed. This is a meaningful loss of optionality regardless of how it's framed. (Note: the call transcript renders the CFO's self-introduction as "Mark Mendoza," which appears to be an ASR error; the company's press release identifies him as Marc E. Binda.)

Wind-downs were reclassified from cyclical to structural. Joel reframed the underlying behavior: "this is the first time that companies have really more aggressively, not at the public level, but at the private level, tried to combine companies or wind down companies that they feel that the opportunities for the marketplace just aren't there." The semantic shift — from "capital-constrained" (cyclical) to "aggressive wind-downs" (permanent capital discipline) — implies the demand floor sits lower than the 2026 guide contemplates.

AI framing nudged tentatively bullish for the first time. Joel offered: "most experts believe that AI will have a small impact on real estate requirements and could even see the need for additional dry and wet space as they run experiments designed by AI." This is hedged but represents the first attempt to position AI as potentially additive to lab demand. Given the otherwise defensive posture, the AI framing reads as a search for a positive forward narrative rather than a thesis with operational evidence behind it.

The hedging vocabulary deepened to acknowledge limits of visibility. "Subject to a variety of unpredictable tenant wind downs," "we are carefully evaluating critical construction milestones," "a lot will really just depend on where the industry goes" — this is materially more hedged framing than the prior quarter's "telegraphed trough." Management committed to a Q4 FY2026 FFO trough of $1.40–$1.60 three months ago; this quarter the language admits the path to that trough has more variability than disclosed in January.